Abstract
Numerous mutations have been observed in the Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase (RTK) in both germline and sporadic neuroblastoma. Here, we have investigated the Y1278S mutation, observed in four patient cases, and its potential importance in the activation of the full length ALK receptor. Y1278S is located in the 1278-YRASYY-1283 motif of the ALK activation loop, which has previously been reported to be important in the activation of the ALK kinase domain. In this study, we have characterized activation loop mutations within the context of the full length ALK employing cell culture and Drosophila melanogaster model systems. Our results show that the Y1278S mutant observed in patients with neuroblastoma harbors gain-of-function activity. Secondly, we show that the suggested interaction between Y1278 and other amino acids might be of less importance in the activation process of the ALK kinase than previously proposed. Thirdly, of the three individual tyrosines in the 1278-YRASYY-1283 activation loop, we find that Y1283 is the critical tyrosine in the activation process. Taken together, our observations employing different model systems reveal new mechanistic insights on how the full length ALK receptor is activated and highlight differences with earlier described activation mechanisms observed in the NPM-ALK fusion protein, supporting a mechanism of activation more in line with those observed for the Insulin Receptor (InR).
Highlights
Anaplastic lymphoma kinase was first discovered in 1994 as a fusion partner for nucleophosmin (NPM) in anaplastic large cell lymphoma (ALCL) [1,2]
We propose that the activation loop of the full length Anaplastic Lymphoma Kinase (ALK) receptor is mechanistically more similar to that of the Insulin Receptor (InR) than the NPM-ALK fusion protein
Mutation of tyrosine 1278 to serine—Y1278S—in the activation loop of the ALK has been reported in four independent neuroblastoma cases
Summary
Anaplastic lymphoma kinase was first discovered in 1994 as a fusion partner for nucleophosmin (NPM) in anaplastic large cell lymphoma (ALCL) [1,2]. ALK has since been associated with a plethora of human malignancies, including both familial and sporadic neuroblastoma, which is a childhood cancer of the sympathetic nervous system [3,4,5,6]. Characterization of the different point mutations in ALK observed in neuroblastoma patients has led to segregation of mutations into three classes; ligand independent, ligand dependent. Cancers 2017, 9, 149 and kinase dead forms of receptor [5,10]. The majority of these ALK point mutations are localised in the kinase domain of ALK, and include the three hot-spot mutations at residues F1174, F1245, and
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.